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Abstract. Objective and Design: This study examined he
role of nitric oxide in changes in airway physiology and
inflammation in a murine model of fungal allergy induced by
Aspergillus fumigatus (A. fumigatus) by treatment of A.
fumigatus-sensitized mice with NG-nitro-L-arginine methyl
ester (L-NAME) or D-NAME (8 mg/kg; i.p.).
Materials and Methods: Female CBA/J mice received A.
fumigatus antigen dissolved in incomplete Freund’s adjuvant
(10 mg/100 ml i.p. and s.c.) followed 2 weeks later by A.
fumigatus antigens (20 mg; i.n.) and a subsequent i. t. chal-
lenge 4 days later. Airway physiology and inflammation were
examined (24 to 72 h) following i. t. challenge. 
Results: L-NAME-treated mice had lower lung nitrite levels
24 h after A. fumigatus challenge, but higher airway hyper-
responsiveness and inflammation compared to D-NAME
controls. Airway inflammation in the L-NAME treatment
group (72 h) was characterized by a greater bronchoalveolar
lavage (BAL), peribronchial eosinophilia and augmented
levels of CC chemokines compared to controls. 
Conclusions: These findings suggest that nitric oxide is an
important modulator of airway hyperresponsiveness, inflam-
mation and C–C chemokine generation during allergic air-
way responses to A. fumigatus.
Key words: Aspergillus fumigatus – Nitric Oxide – Eosino-
phil – Asthma – Chemokines 
Introduction
Numerous clinical studies have demonstrated that exhaled
nitric oxide is a non-invasive marker of airway inflammation
associated with asthma and other allergic airway diseases
[1–4]. Exhaled nitric oxide is derived predominately from
endothelial (NOS III) and neural (NOS I) sources in normal
airways [5], while the increased concentration of nitric oxide
in asthmatic airways appears to be a consequence of in-
ducible NOS (NOS II) expression [6]. The majority of
clinical and experimental studies suggest that changes in
nitric oxide levels in exhaled air reflects the inflammatory
activity in asthma [3], and is influenced by anti-inflam-
matory therapy. It has also been suggested that specific NOS
II inhibitors may represent a viable treatment option for
asthma and other allergic diseases [6]. However, dissenting
findings from clinical and experimental studies suggest that
nitric oxide lacks a clear deleterious role and may even exert
important modulatory effects during allergic airway disease.
For example, gas-exchange impairment in asthma did not
appear to be related to nitric oxide concentrations in exhaled
air, nor did ventilation-perfusion disturbances appear to cor-
relate to increased nitric oxide synthesis in the airways of
asthmatics [7]. In addition, acute inhibition of nitric oxide
has been shown to exacerbate allergen-induced airway hyper-
reactivity in a guinea pig model of asthma [8]. Thus, further
investigation into the role of nitric oxide during allergic
airway disease is warranted in light of these controversial
findings.
Chemokines are unique cytokines that promote the
recruitment of leukocytes to sites of acute and chronic
inflammation [9]. The C–C chemokine subfamily, charac-
terized by the conserved juxtaposition of two cysteine
residues in their NH2-terminal end, have recently emerged as
important mediators of allergic airway inflammation [10].
During asthmatic attacks, C–C chemokines such as mono-
cyte chemotactic peptide-1 (MCP-1), macrophage inflam-
matory protein-1 alpha (MIP-1a), RANTES (regulated upon
activation in normal T cells expressed and secreted) and
eotaxin have been found to be transiently increased in the
bronchoalveolar lavage (BAL) [11–14]. Experimental models
of allergic airway inflammation have further revealed distinct
roles for MCP-1, MIP-1a and RANTES in the trafficking of 
T lymphocytes, monocytes and eosinophils around the air-
ways, thereby affecting the severity of airway inflammation
and hyperresponsiveness [15–19]. Other experimental
studies support a role for the C–C chemokine eotaxin in the
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selective recruitment and activation of eosinophils during
allergic airway responses [20–22]. While C–C chemokines
represent a major target during allergic airway responses,
little is presently known about the endogenous regulation of
these mediators during allergic airway disease. 
Thus, we examined the effect of nitric oxide on the
allergic airway response to the ubiquitous fungal organism
Aspergillus fumigatus (A. fumigatus). Inhalation of fungal
spores by individuals previously sensitized to A. fumigatus
antigens results in an allergic disease with similar charac-
teristics to asthma. This disease is characterized by a Th2-
type cytokine response with varying severity of bronchial
hyperresponsiveness, eosinophilia, and elevations in im-
munoglobulin E (IgE) [23–26]. We have recently developed
an experimental model of fungal-induced asthma and have
previously reported that the C–C chemokines MCP-1,
eotaxin and C10 are significantly elevated in the lungs of
mice experiencing pulmonary allergic responses to soluble
A. fumigatus antigens [27]. We have also discovered that the
immunoneutralization of C10 significantly attenuates the
airway inflammation and hyperresponsiveness associated
with experimental showing that chemokines are relevant
participants in A. fumigatus-induced allergic airway disease
[27]. In the present study, we demonstrate that nitric oxide is
also relevant to experimental fungal asthma since acute in-
hibition of nitric oxide exacerbated the airway hyperrespon-
siveness, eosinophilic and lymphocytic inflammation, and
C–C chemokine generation associated with this model of
allergic airway disease. 
Materials and methods
Murine model of fungal asthma
Specific-pathogen free (SPF), female CBA/J mice were purchased from
Jackson Laboratories (Bar Harbor, ME) and were kept in a SPF facility
for the duration of these experiments. Prior approval for mouse usage in
these studies was obtained from University Laboratory Animal Medi-
cine facility at the University of Michigan Medical School. Sensi-
tization of mice to soluble A. fumigatus antigens was achieved as
previously described [16–28]. Briefly, a total of forty mice received 
a total of 10 mg of A. fumigatus crude antigen (Greer Laboratories,
Lenoir, NC) dissolved in 0.2 ml of incomplete Freund’s adjuvant (Sigma
Chemical Company, St. Louis, MO). All mice were subsequently sen-
sitized to this A. fumigatus preparation via 0.1 ml intraperitoneal and
subcutaneous injections, and two weeks later each mouse received a
total of 20 mg of A. fumigatus antigens dissolved in normal saline via the
intranasal route. Four days after the intranasal challenge, sensitized
mice were challenged with 20 mg of A. fumigatus antigen dissolved in
normal saline via the intratracheal route. Non-sensitized mice were used
as controls and received normal saline alone via the same routes and
over the same time periods. 
Acute pharmacological inhibition of nitric oxide 
We have previously used L-NAME to non-selectively inhibit nitric
oxide synthesis in a number of in vivo models [29–31]. D-NAME is a
structural enantiomer of L-NAME that lacks nitric oxide synthase in-
hibitory actions [32] and was administered to control mice in this study.
L-NAME was administered to 20 mice at a dose of 8 mg/kg [31] via an
intraperitoneal injection immediately following the intratracheal A.
fumigatus or normal saline challenge. An equal number of A. fumigatus
sensitized and challenged mice received a similar dose of D-NAME at
the same time. 
Nitrite and nitrate assay
Previous clinical studies have demonstrated that nitrite and nitrate levels
may be a more useful measure of nitric oxide production due to the fact
that exhaled may not reflect total nitric oxide production [33]. Nitrite
and nitrate are stable end products of nitric oxide metabolism and were
measured in the present study using a technique supplied by Oxford
Biomedical Research (Oxford, MI). Briefly, 50 ml of supernatants from
bronchoalveolar lavage (BAL) samples were deproteinized with ZnSO4
for 15 min at room temperature. Deproteinated supernatants were
subsequently transferred to microcentrifuge tubes containing cadmium
beads for the quantitative conversion of nitrate to nitrite. Cadmium-
treated supernatants (50 ml) were finally transferred to a microtiter
plate, and 100 ml of Griess reagent containing equal parts of 1% sul-
fanilamide in 25% (vol/vol) phosphoric acid and 0.01 N-1-napthylethyl-
enediamine dihydrochloride in distilled water was added for 10 min.
Microtiter plates were read at 540 nm in a microtiter plate reader. Nitrite
and nitrate concentrations were calculated from a standard curve using
sodium nitrite, and the sensitivity of this assay consistently approached
1 mM.
Determination of systemic IgE
Sera from non-sensitized and A. fumigatus-sensitized mice were
analyzed for total IgE. A. fumigatus-sensitized mice were also
monitored for changes in total IgE after receiving an intratracheal A.
fumigatus challenge. Complimentary capture and detection antibody
pairs for mouse IgE were obtained from PharMingen (San Diego, CA)
and the IgE ELISA was performed according to the manufacturer’s
directions. Duplicate sera samples were diluted 1:100 and IgE levels in
each were calculated from optical density readings at 492 nm, and IgE
concentrations were calculated from a standard curve generated using
recombinant IgE (5–2000 pg/ml).
Measurement of bronchial hyperresponsiveness
Immediately prior to and at 24, 48, and 72 h after the intratracheal A.
fumigatus challenge, bronchial hyperresponsiveness in A. fumigatus-
sensitized mice was assessed in a Buxco plethysmograph (Buxco, Troy,
NY) specifically designed for the low tidal volumes of mice [17].
Sodium pentobarbital (Butler Co., Columbus, OH; 0.04 mg/g of mouse
body weight) was used to anesthetize mice prior to their intubation for
ventilation with a Harvard pump ventilator (Harvard Apparatus, Reno,
NV). The following ventilation parameters were employed for each
mouse: tidal volume = 0.25 ml, breathing frequency = 120/min, and
positive end-expiratory pressure >3 cm H2O. Within the sealed plethys-
mograph mouse chamber, transpulmonary pressure (i.e. D tracheal
pressure – D mouse chamber pressure) and inspiratory volume or flow
were monitored online with an adjacent computer. Airway resistance
was continuously calculated online via specialized computer software
(Buxco, Troy, NY), and was determined by the division of the transpul-
monary pressure by the change in inspiratory volume. Following a base-
line period in the Buxco apparatus, all mice received a dose of 10 mg of
methacholine by tail vein injection, and airway responsiveness to this
non-selective bronchoconstrictor was again calculated online. Because
non-sensitized mice typically exhibited minor (i.e. less than a 1.5-fold)
increases above the baseline airway resistance response following the
injection of 10 mg of methacholine, this dose of methacholine was sub-
sequently used to reveal changes in airway hyperresponsiveness in both
fungal asthma models. At the conclusion of the assessment of airway
responsiveness, a bronchoalveolar lavage (BAL) was performed with
1 ml of normal saline. Approximately 500 ml of blood from each mouse
was also transferred to a microcentrifuge tube, and sera were obtained
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after the sample was centrifuged at 15000 rpm for 10 min. Whole lungs
were subsequently dissected from each mouse and snap frozen in liquid
N2, or prepared for histological analysis. 
BAL and lung histological analysis
Neutrophils, macrophages, eosinophils, and lymphocytes were quan-
tified in BAL samples obtained by i. t. instillation of 1 ml saline 
(BAL recovery was consistent between groups) applied to coded
microscope slides using a cytospin (Shandon Scientific, Runcorn,
UK). Identification of each cell type in the cytospins was facilitated by
Wright-Giemsa differential stain, and average number of each cell type
per animal was determined in 8 high-powered fields (HPF; 1000 X) on
every slide.
Whole lungs from normal (i.e. non-sensitized) and A. fumigatus-
sensitized prior to and after A. fumigatus challenge were fully inflated 
by the intratracheal perfusion with 4% paraformaldehyde. Lungs were
then dissected and placed in fresh paraformaldehyde for 24 h. Routine
histological techniques were used to paraffin-embed this tissue, and
5 mm sections of whole lung were counterstained with Mayer’s hema-
toxylin (Mayer & Myles Laboratories, Coopersburg, PA). Inflammatory
infiltrates and other histological changes were examined around 
blood vessels and airways using light microscopy at a magnification of
1000X (high-powered field; hpf). Eosinophils were counted in a mini-
mum of 20 randomly selected hpf using a multiple step-analysis of
coded whole lung histologic sections. Eosinophils in juxtaposition to
the airway were counted since the eosinophilic inflammation in this
fungal-induced asthma model was exclusively associated with bron-
chioles or larger airways. 
Chemokine and cytokine ELISA analysis
Murine MCP-1, eotaxin and C10 protein levels were determined in 
50 ml of BAL supernatants using a standardized sandwich ELISA tech-
nique previously described in detail [34]. Briefly, Nunc-immuno ELISA
plates (MaxiSorpTM) were coated with the appropriate capture antibody
(R&D Systems, Minneapolis, MN) at a dilution of 1–5 mg/ml of
coating buffer (in M: 0.6 NaCl; 0.26 H3BO4; 0.08 NaOH; pH 9.6) over-
night at 4°C. The unbound capture antibody was washed away and each
plate was blocked with 2% BSA-PBS for 90 min at 37°C. Each ELISA
plate was then washed with PBS tween 20 (0.05%; vol/vol), and 50 ml
samples either undiluted or diluted 1:10 were added to duplicate wells
and incubated for 1 h at 37°C. Following the incubation period, the
ELISA plates were then thoroughly washed and the appropriate bio-
tinylated polyclonal rabbit antibody (3.5 mg/ml) was added. After
washing the plates 30 min later, streptavidin-peroxidase (Bio-Rad
Laboratories, Richmond, CA) was added to each well for 30 min, and
each plate was thoroughly washed again. Chromagen substrate (Bio-
Rad Laboratories) was added and optical readings at 492 nm were ob-
tained using an ELISA plate scanner. Recombinant murine cytokines
and chemokines were used to generate the standard curves from which
the concentrations present in the samples were derived. The limit of
ELISA detection for each cytokine and chemokine was consistently
above 50 pg/ml. Each ELISA was screened to ensure the specificity of
each antibody used. 
Data statistical analysis
All results are expressed as mean ± standard error of the mean (SE).
Treatment groups were compared by analysis of variance (ANOVA).
Dunnett’s test for multiple comparisons was then used to determine
statistical significance between the control and experimental groups at
each time point after A. fumigatus challenge; P < 0.05 was considered
statistically significant.
Results
Acute pharmacological inhibition of nitric oxide with 
L-NAME during experimental fungal asthma
BAL samples from normal mice contained approximately 1.3
± 0.5 mM of nitrite and these levels were similar to BAL nitrite
levels measured in A. fumigatus-sensitized immediately prior
to A. fumigatus intratracheal challenge (nitrite levels within
the fluid used for lavage were below the level of detection
with this assay). At 24 h after the intratracheal antigen chal-
lenge, mice that were treated with D-NAME exhibited sig-
nificantly higher (P ≤ 0.05; 7.7 ± 2.2 mM) BAL levels of
nitrites compared with normal mice (Fig. 1). At the same time,
nitrite levels in BAL samples from L-NAME-treated mice
were 3.7 ± 0.1 mM, or approximately 50% lower than the
levels measured in the untreated and D-NAME-treated mice.
The levels of nitrite measured in the L-NAME-treated group
were not different from levels measured in non-sensitized
(normal) mice. However, BAL levels of nitrites in L-NAME
and D-NAME-treated mice were not statistically different at
48 and 72 h after intratracheal A. fumigatus antigen challenge,
confirming that the pharmacological inhibition of nitric oxide
synthesis was probably limited to the first 24 h after the intra-
tracheal A. fumigatus challenge (data not shown).
L-NAME treatment did not affect circulating IgE levels in
experimental fungal asthma
Levels of total IgE in sera were approximately 20 ng/ml in
non-sensitized mice. Total IgE level in all mice with fungal-
induced asthma was significantly (p ≤ 0.05) greater than
levels measured in non-sensitized mice, but differences be-
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Fig. 1. Nitrite levels in bronchoalveolar lavage (BAL) from normal
mice (i.e. non-sensitized) and mice sensitized to A. fumigatus. Sen-
sitized mice received L-NAME or D-NAME, and BAL was collected
from each ABPA group at 24 h after intratracheal A. fumigatus chal-
lenge. Values represent mean ± SE of 3–5 mice per treatment group.
*P ≤ 0.05 compared with normal mice. t P ≤ 0.05 compared with D-
NAME-treated A. fumigatus-sensitized mice.
tween the sensitized groups were not detected (Fig. 2). These
observations suggested that the acute inhibition of nitric
oxide during experimental fungal asthma did not exacerbate
the allergic IgE response to A. fumigatus. 
L-NAME treatment significantly enhanced airway hyper-
responsiveness in experimental fungal asthma
Airway hyperresponsiveness prior to and at 24, 48 and 72 h
following the intratracheal A. fumigatus challenge was reveal-
ed by the intravenous delivery of 10 mg of b-methacholine, 
a smooth muscle spasmogen. Immediately prior to the A.
fumigatus challenge, sensitized mice given intravenous
methacholine exhibited an approximate 2-fold increase in
airway resistance above that measured before methacholine
administration (Fig. 3). Airway resistance was significantly
enhanced above the baseline response in non-sensitized
mice. However, L-NAME-treated mice exhibited a 15-fold
increase in airway hyperresponsiveness, whereas similarly
challenged D-NAME-treated mice showed a 5-fold increase
in airway responsiveness to methacholine (Fig. 3). Further-
more, at the 48 and 72 h time points after A. fumigatus
challenge, airway responses to methacholine stimulation 
in L-NAME-treated mice remained approximately 3-fold
greater than the airway responses measured in their D-
NAME counterparts. Thus, the acute inhibition of nitric
oxide synthesis with L-NAME augmented and prolonged the
airway hyperresponsiveness associated with experimental
fungal-induced asthma.
Acute inhibition of nitric oxide prolongs BAL and peri-
bronchial eosinophilia in experimental fungal-induced asthma
Leukocyte counts in cytospins from non-sensitized (or
normal), and A. fumigatus-sensitized and challenged mice
are shown in Figure 4. Twenty-four hours after the intra-
tracheal introduction of A. fumigatus into sensitized mice,
BAL samples contained eosinophils, lymphocytes, neutro-
phils and macrophages while BAL from normal mice only
contained macrophages (Fig. 4A). No significant differences
in leukocyte counts were detected among the sensitized
groups at 24 h after A. fumigatus challenge. At the 72 h time
point, all four types of leukocytes were again present in the
sensitized groups, but the numbers of eosinophils and
lymphocytes were significantly increased in the L-NAME-
treated group compared with the D-NAME treated group
(Fig. 4B). Similar leukocyte counts were present in BAL
samples from the untreated and D-NAME-treated groups.
Thus, these data suggested that the acute inhibition of nitric
oxide synthesis was associated with the persistent accumula-
tion of eosinophils and lymphocytes in the BAL of A. fumi-
gatus-sensitized mice. 
Although few eosinophils were localized around the air-
ways of A. fumigatus-sensitized mice immediately prior to
the A. fumigatus challenge (not shown), a profound accumu-
lation of eosinophils was apparent in both sensitized groups
at 24 h after the A. fumigatus challenge (Fig. 5). However, the
profound airway eosinophilia in the L-NAME-treated group
persisted out to 72 h after A. fumigatus challenge, unlike the
other two sensitized groups (Fig. 5). These data suggested
that the acute inhibition of nitric oxide synthesis markedly
affected the recruitment and persistence of eosinophils
around allergic airways.
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Fig. 2. Sera IgE levels in normal mice (i.e. non-sensitized) and mice
with A. fumigatus-induced asthma. Allergic mice received L-NAME or
D-NAME, and sera were collected from each ABPA group at 24 h after
intratracheal A. fumigatus challenge. Total IgE was measured using a
specific ELISA (see Materials and Methods). Values represent mean SE
of 3–5 mice per treatment group. *P ≤ 0.05 compared with the control
in normal mice. 
Fig. 3. Airway hyperresponsiveness in A. fumigatus-sensitized mice
prior to and after A. fumigatus (Asp) intratracheal (i. t.) challenge, and
L-NAME or D-NAME treatment. Airway hyperresponsiveness or
resistance in all A. fumigatus -sensitized mice was revealed by the intra-
venous administration of 10 mg of methacholine. A. fumigatus-sen-
sitized mice showed an approximate 2-fold increase in airway resistance
above baseline immediately prior to an intratracheal A. fumigatus chal-
lenge (at T = 0). However, at 24 to 72 h after A. fumigatus challenge, the
L-NAME treated group exhibited a 15-fold increase in airway
resistance above baseline, and this response was significantly greater
than the airway hyperresponsiveness measured in D-NAME treated
mice. Values represent mean of 3–5 mice per treatment group.
*P ≤ 0.05 compared with D-NAME treatment group at the same time
points. 
L-NAME treatment significantly increased pulmonary CC
chemokine levels in allergic mice
Previous studies suggested that the increased pulmonary
expression of MCP-1, eotaxin and C10 are associated with
the development and progression of experimental allergic
responses to A. fumigatus antigens [27]. Also, from these
previous studies it was observed that C10 has a prominent
role in the development of experimental fungal-induced
asthma. In the present study, all three chemokines were
detected in BAL samples from A. fumigatus sensitized mice
prior to the intratracheal challenge with A. fumigatus. In
contrast, eotaxin and C10 were the only two chemokines
detected in BAL samples from non-sensitized mice
(Fig. 6B, C; dashed line). The acute inhibition of nitric oxide
synthesis with L-NAME significantly (p ≤ 0.05) increased
the levels of MCP-1 (Fig. 6A), eotaxin (Fig. 6B) and C10
(Fig. 6C) above levels of these chemokines in BAL samples
from D-NAME-treated mice. Only MCP-1 was significantly
elevated at 48 h after A. fumigatus challenge. All three CC
chemokines were either below the level of detection or at
baseline levels in both NAME treatment groups at 72 h after
the intratracheal A. fumigatus challenge (Fig. 6A)
Discussion
Allergic responses to A. Fumigatus conidia in asthmatics is a
common phenomena. A. Fumigatus is a major indoor and
outdoor mould that can promote respiratory problems and
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Fig. 4. Leukocyte counts in bronchoalveolar lavage (BAL) from non-sensitized (or normal) and mice with A. fumigatus-induced asthma treated with
L-NAME or D-NAME. Eosinophils, macrophages, lymphocytes and neutrophils per animal were counted in a minimum of 8 high powered fields
(HPF) from 3–5 mice from both treatment groups. Only macrophages were observed BAL samples from normal mice, but significantly increased
numbers of eosinophils, lymphocytes and neutrophils were present in both treatment groups at 24 h after A. fumigatus challenge (Panel A). However,
at 72 h after A. fumigatus challenge, eosinophils and lymphocytes remained significantly elevated in the L-NAME-treated group compared with the
D-NAME group (Panel B). *P ≤ 0.05 compared with the D-NAME-treated mice with A. fumigatus-induced asthma at 72 h after A. fumigatus chal-
lenge.
Fig. 5. Quantification of peribronchial eosinophils in histological sec-
tions from the lungs of untreated, L-NAME- and D-NAME-treated mice
with fungal-induced asthma. Eosinophils were counted in a minimum of
25 high powered fields (hpf) from multiple tissue sections in all three A.
fumigatus-induced asthmatic groups. Although eosinophils were never
observed in histological sections from the lungs of normal mice, pro-
foundly increased numbers of eosinophils were present in both ABPA
groups at 24 h after A. fumigatus challenge. However, at 72 h after 
A. fumigatus challenge, peribronchial eosinophilia in the L-NAME-
treated group was significantly greater compared with the other two
allergic groups. t P ≤ 0.05 compared with D-NAME-treated mice with
A. fumigatus-induced asthma at 72 h after A. fumigatus challenge.
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Fig. 6. MCP-1 (A), eotaxin (B), and C10 (C) protein levels in BAL
samples immediately prior to and at various times after an intratracheal
A. fumigatus-challenge, and L-NAME or D-NAME treatment in A.
fumigatus-sensitized mice. The acute inhibition of nitric oxide with 
L-NAME significantly increased immunoreactive levels of MCP-1,
eotaxin and C10 above levels measured in the D-NAME controls. Values
represent mean ± SE of 3–5 mice per treatment group. Dashed lines
denote mean levels of each CC chemokine in BAL from normal mice
(Eotaxin = 0.50 ± 0.01 ng/ml; C10 = 0.7 ± 0.01; no MCP-1). *P ≤ 0.05
compared with D-NAME treatment group at the same time point. 
can increase the risk of symptomatic allergic disease in
asthmatics and patients with cystic fibrosis [35, 23, 24]. Symp-
toms, similar to those in asthma, include recurrent episodes of
wheezing, mucus production, inflammatory infiltrates around
the airways, elevated IgE, and increased Th2-type cytokines
such as IL-4, IL-5 and IL-10 [36]. In contrast to patients with
the clinical syndrome allergic bronchopulmonary aspergil-
losis, or ABPA, however, chronic colonization of the airways
by A. fumigatus does not occur. Murine models have been
developed that exhibit many of the features of clinical ABPA,
however little is known about the immune mechanisms that
regulate A. fumigatus-induced asthma [37–41]. Furthermore,
previous studies have not addressed the role of nitric oxide in
this disease. In the present study, A. fumigatus-sensitized and
-challenged mice treated with L-NAME exhibited signifi-
cantly greater airway hyperresponsiveness and eosinophilic
inflammation than their D-NAME-treated counterparts. The
augmented airway physiology and eosinophilic inflammation
after L-NAME treatment were also associated with signifi-
cantly greater levels of potent chemoattractant C–C chemo-
kines such as MCP-1, eotaxin and C10 in the BAL. Thus, the
present findings suggest that nitric oxide is an important
modulator of many facets of allergic disease induced by A.
fumigatus. Recent evidence from a study conducted by De
Sanctis et al. [42] using mice with targeted deletions of the
three known isoforms of NOS (NOS I, II, and III), identified
the NOS I isoform to be important in protection from airway
hyperresponsiveness in an ovalbumin model of allergic
asthma. It is possible that distinct NOS isoforms are involved
in the observations reported in this present study and this area
of study is currently being investigated.
The kinetics of leukocyte accumulation around airways
during clinical asthma [10, 12] and experimental allergic air-
way inflammation [15] correlates with the increased pulmo-
nary expression of C–C chemokines. Cellular sources of
C–C chemokines during airway inflammation include pul-
monary immune and non-immune cells such as alveolar
macrophages, airway epithelial cells, lung (myo) fibroblasts,
and smooth muscle cells [15]. Immunoneutralization studies
in experimental allergic airway models have shown that
MCP-1 is a potent T cell recruitment factor [15–19], whereas
eotaxin [20–43], RANTES [16], and MIP-1a [16] promote
the accumulation of eosinophils around allergic airways.
Recent studies in this laboratory have suggested that specific
C–C chemokines are also important participants during the
development and progression of allergic airway responses to
A. fumigatus [27]. The immunoneutralization of C10 revealed
that this novel IL-4-inducible chemokine [44] had a sig-
nificant effect on the airway reactivity and eosinophil and
lymphocyte recruitment during experimental fungal-induced
asthma [27]. In the present study, C10 was the most promi-
nent C-C chemokine detected in the BAL following A. fumi-
gatus challenge and D-NAME treatment. However, C10
levels in the D-NAME treatment group were significantly
(i.e. 3-fold) lower than levels of this chemokine in BAL
samples from allergic mice treated with L-NAME. While it is
possible that increased C10 levels following L-NAME treat-
ment accounted for the augmented airway hyperresponsive-
ness and eosinophil and lymphocyte recruitment in the al-
lergic airways, MCP-1 and eotaxin were also significantly
elevated in this group. Recent studies in this laboratory have
shown that MCP-1 mediates allergic airway inflammation,
and more importantly, MCP-1 directly induces airway hyper-
responsiveness in the absence of underlying allergic disease
[45]. The effects of eotaxin in murine models of allergic air-
way disease are well documented [19, 20], and this chemo-
kine is one of the most potent eosinophil chemoattractants
yet described [46]. Thus, in the context of reduced nitrogen
oxide levels in the lung, the C–C chemokines MCP-1,
eotaxin and C10 were significantly increased during airway
allergic responses to A. fumigatus, and these changes may
have accounted for the exacerbated airway hyperrespon-
siveness and inflammation in this model of fungal-induced
asthma. The mechanism of increased chemokine production
following reduced NO levels in the lung may be a reflection
of increased NF-kB activation. NO has recently been shown
to increase IkB activation, a NF-kB inhibitory factor, and
hence decrease NF-kB activity [47].
Given that a large number of C–C chemokines appear to
work in a coordinated manner [17, 19] and exhibit a dif-
ferential pattern of expression [20] during allergic airway
responses, targeting a single chemokine may not provide a
clear therapeutic effect in the more complex clinical allergic
airway diseases. Therefore, one strategy for collectively
regulating the generation of several C–C chemokines during
pulmonary allergic responses may involve the regulation of
endogenous nitric oxide synthesis. Abundant evidence pre-
sently exists demonstrating that nitric oxide inhibits C–C
chemokine in a number of cells during diverse inflammatory
reactions. In vitro experiments have shown that nitric oxide
inhibits MCP-1 generation by the vascular endothelium
[48–49], by peritoneal macrophages [31], and MIP-1a
synthesis by alveolar macrophages [50]. In addition, the sup-
pressive effect of induced nitric oxide on MCP-1 and C10
generation was observed at day 4 [30] and day 8 [51] in a 
Th-1 type pulmonary granuloma model. Interestingly, nitric
oxide has also been shown to regulate the synthesis of 
C-X-C chemokines during acute inflammatory responses in
the peritoneal cavity [52]. Thus, the results from the present
study appear to coincide with previous observations that
nitric oxide regulates the generation of CC chemokines such
as MCP-1, eotaxin and C10. 
In conclusion, the results from the present study demon-
strate that endogenous nitric oxide generation has a major
effect on the generation of allergic airway responses to A.
fumigatus. The acute inhibition of nitric oxide using a phar-
macological inhibitor aggravated airway inflammation and
hyperresponsiveness, and these responses were associated
with significantly enhanced C–C chemokine levels in the air-
ways. Thus, the discovery that nitric oxide modulates the
generation of a number of CC chemokines that could poten-
tially contribute to the inflammatory events during clinical
allergic airway disease provides impetus to further investigate
the best strategy for regulating nitric oxide production in
clinical asthmatic and allergic airway diseases.
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